Modifies provisions relating to the ordering and administration of ketamine for mental health purposes
Summary
HB 3055 revises Missouri’s controlled-substances prescribing law, section 195.070, to address who may order and administer ketamine hydrochloride for mental health purposes. The bill keeps the general framework allowing physicians and certain other licensed practitioners to prescribe, administer, and dispense controlled substances in the course of professional practice, and it preserves existing limits on advanced practice registered nurses, including restrictions on Schedule II prescribing and the prohibition on prescribing for themselves or family members.
The bill’s main new provision is a set of specific restrictions on ketamine used for mental health treatment. It would prohibit a physician from delegating the authority to order ketamine hydrochloride for mental health purposes to another individual, require a physician to be on site and immediately available if a certified registered nurse anesthetist administers ketamine, and require a documented physician diagnosis and treatment plan before intravenous ketamine may be administered for mental health purposes. The bill also continues existing rules on controlled substances, including limits on accepting unused medication and bans on self-prescribing except in a medical emergency.
Impact
HB 3055 would amend Missouri’s controlled-substances statute by creating explicit state-law requirements for ketamine hydrochloride when used for mental health treatment. It would narrow delegation and supervision practices for ketamine administration, especially in settings using certified registered nurse anesthetists, and would add a physician-diagnosis-and-treatment-plan prerequisite for intravenous ketamine. The bill affects physicians, nurse anesthetists, advanced practice registered nurses, and any facilities or clinics providing ketamine-based mental health services.
Sentiment
Based on the available context, the bill appears to have been introduced and referred to the House Health and Mental Health Committee without recorded votes or committee testimony in the provided materials. The caption suggests a regulatory and patient-safety focus rather than a broad expansion of access, and the bill’s structure indicates an effort to clarify professional boundaries around ketamine treatment. Because no transcripts or vote totals are available, there is no documented public sentiment in the record provided beyond the bill’s referral status.
Contention
The likely points of contention are the bill’s limits on delegation and its requirement that a physician be physically on site and immediately available when a certified registered nurse anesthetist administers ketamine. Supporters would likely view these provisions as safeguards for patient safety and oversight in mental health treatment, while opponents may see them as restricting clinical flexibility and limiting access to ketamine therapy. Another possible area of debate is the requirement for a documented physician diagnosis and treatment plan before intravenous ketamine can be used, which could be viewed as adding administrative and clinical hurdles.